What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
<p>Abstract</p> <p>Coronary artery disease in the transplanted heart, also known as cardiac allograft vasculopathy (CAV), is one of the major causes of mortality late after transplantation. It affects up to 50% of all heart transplant recipients within 5 years of surgery. The mecha...
| Yazar: | |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
BMC
2000-12-01
|
| Seri Bilgileri: | Current Controlled Trials in Cardiovascular Medicine |
| Konular: | |
| Online Erişim: | http://cvm.controlled-trials.com/content/1/3/166 |